直肠癌新辅助治疗强化二期试验的系统综述
该系统综述评估了2004至2016年间92项局部晚期直肠癌新辅助长程放疗或放化疗治疗强化的二期试验设计。作者认为亟需改进未来二期试验设计并增加随机试验。
要点
- 92项二期试验中仅12项(13.0%)为随机设计,8项设标准治疗对照臂。
核心结论
- 亟需改进未来直肠癌二期试验设计,显著增加随机试验以克服选择偏倚并确定适合三期试验的新方案。
研究设计与样本
- 系统检索PubMed、EMBASE、MEDLINE和Cochrane Library数据库2004至2016年发表的局部晚期直肠癌新辅助长程放疗或放化疗治疗强化二期试验。
- 共纳入92项符合条件的试验,评估试验临床设计、结局、统计设计与依从性,并对pCR进行多变量荟萃回归分析。
主要发现
- 87项试验(94.6%)纳入AJCC II期和III期等效疾病患者,43项试验(46.7%)强制要求MRI局部分期。
- 仅12项试验(13.0%)为随机设计,其中8项设标准治疗对照臂。
- 仅51项试验(55.4%)描述统计设计,21项试验(22.8%)未报告样本量推导。
- 84项试验(91.3%)定义主要终点,但使用了15种不同的主要终点;所有试验均报告pCR率。
- 仅38项试验(41.3%)充分报告试验统计设计与依从性。
临床怎么用
- 设计直肠癌新辅助治疗强化二期试验时应优先采用随机对照设计并设标准治疗对照臂。
- 应充分报告统计设计、样本量推导和试验依从性,并统一主要终点定义。
- 高放疗剂量可能与更高pCR率相关,但需在三期试验中验证。
局限性
- 综述未报告所纳入试验的样本量、具体放疗剂量数值及各项试验的详细偏倚风险评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Multiple phase 2 trials of neoadjuvant treatment intensification in locally advanced rectal cancer have reported promising efficacy signals, but these have not translated into improved cancer outcomes in phase 3 trials. Improvements in phase 2 trial design are needed to reduce these false-positive signals. This systematic review evaluated the design of phase 2 trials of neoadjuvant long-course radiation or chemoradiation therapy treatment intensification in locally advanced rectal cancer. METHODS AND MATERIALS: The PubMed, EMBASE, MEDLINE, and Cochrane Library databases were searched for published phase 2 trials of neoadjuvant treatment intensification from 2004 to 2016. Trial clinical design and outcomes were assessed, with statistical design and compliance rated using a previously published system. Multivariable meta-regression analysis of pathologic complete response (pCR) was conducted. RESULTS: We identified 92 eligible trials. Patients with American Joint Committee on Cancer stage II and III equivalent disease were eligible in 87 trials (94.6%). In 43 trials (46.7%), local staging on magnetic resonance imaging was mandated. Only 12 trials (13.0%) were randomized, with 8 having a standard-treatment control arm. Just 51 trials (55.4%) described their statistical design, with 21 trials (22.8%) failing to report their sample size derivation. Most trials (n=84, 91.3%) defined a primary endpoint, but 15 different primary endpoints were used. All trials reported pCR rates. Only 38 trials (41.3%) adequately reported trial statistical design and compliance. Meta-analysis revealed a pooled pCR rate of 17.5% (95% confidence interval, 15.7%-19.4%) across treatment arms of neoadjuvant long-course radiation or chemoradiation therapy treatment intensification and substantial heterogeneity among the reported effect sizes (I2 = 55.3%, P<.001). Multivariable meta-regression analysis suggested increased pCR rates with higher radiation therapy doses (adjusted P=.025). CONCLUSIONS: Improvement in the design of future phase 2 rectal cancer trials is urgently required. A significant increase in randomized trials is essential to overcome selection bias and determine novel schedules suitable for phase 3 testing. This systematic review provides key recommendations to guide future treatment intensification trial design in rectal cancer.
引用
- Teo MTW, McParland L, Appelt AL, et al. Phase 2 Neoadjuvant Treatment Intensification Trials in Rectal Cancer: A Systematic Review. Int J Radiat Oncol Biol Phys. 2017. PMID: 29254769. doi:10.1016/j.ijrobp.2017.09.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。